Immunicum AB (STO:IMMU), a biopharmaceutical company developing therapeutic cancer vaccines, on Thursday reported that at the Extraordinary General Meeting, held on 8 November 2018, the EGM resolved to approve both the board of directors' resolution on a directed share issue and to approve the board of directors' resolution on a new issue of shares with preferential rights for the shareholders.
Reportedly, the EGM resolved to approve the board of directors' resolution of 16 October 2018 on a new issue of shares with deviation from the shareholders' preferential rights.
This directed issue entails that the company's share capital shall be increased by a maximum amount of SEK1,045,779.40 by issue of at most 20,915,588 new shares. The subscription price is SEK8.50 per share and is deemed to be in accordance with the market.
At full subscription the company will be provided with an amount of approximately SEK178m, before issue expenses.
In addition, the EGM resolved to approve the board of directors' resolution of 16 October 2018 on a new issue of shares with preferential rights for the shareholders.
This rights issue entails that the company's share capital shall be increased by a maximum amount of SEK1,019,170.60 by issue of at most 20,383,412 new shares with preferential rights for the company's existing shareholders. The subscription price is SEK8.50 per share. At full subscription the company will be provided with an amount of approximately SEK173m, before issue expenses.
According to the company, shareholders in the company have preferential right to subscribe for shares whereupon one existing share in the company entitles to one subscription right and five subscription rights entitle to subscribe for two new shares. New shares may also be subscribed for without subscription rights.
The record date for obtaining subscription rights and the right to participate in the new issue of shares with preferential rights is on 21 November 2018. Subscription of shares, both with and without the exercise of subscription rights, is to take place during the period starting on 26 November 2018 up to and including 10 December 2018.
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.
(EUR1.00=SEK10.25)
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV